Skip to main content
. 2023 Apr 21;146(10):4247–4261. doi: 10.1093/brain/awad132

Figure 2.

Figure 2

Effect of bumetanide and minocycline on CCI-induced changes in adult neurogenesis and PV interneuronal loss in the DG. (A) Parvalbumin (PV) labelling (white arrows) at 3 days post-controlled cortical impact (CCI) in the contralesional (top) and ipsilesional (bottom) dentate gyrus (DG) of sham-, CCI vehicle- and CCI bumetanide (Bum)-treated animals (Scale bar = 100 μm). (B) Quantification of PV-positive cells 3 days post-CCI in the contralesional and ipsilesional DG of sham-, CCI vehicle- and CCI bumetanide-treated animals. (C) As for A at 7 days post-CCI with minocycline (Mino)-treated animals added. (D) As for B at 7 days post-CCI. (E) DCX (top) and Nestin (bottom) labelling at 7 days post-CCI in the ipsilesional DG of sham-, CCI vehicle, bumetanide- and minocycline-treated animals (Scale bar = 100 μm). (F) Quantification of DCX-positive cells 7 days post-CCI in the ipsilesional DG of sham-, CCI vehicle-, bumetanide- and minocycline-treated animals. (G) Quantification of Nestin-positive cells 7 days post-CCI in the ipsilesional DG of sham-, CCI vehicle-, bumetanide- and minocycline-treated animals. (H) As for E in the contralesional DG. (I) As for F in the contralesional DG. (J) As for G in the contralesional DG. n = 7 animals per condition, three slices per animal. Data in B, D, F, G and I were analysed using one-way ANOVA with Dunnett's post hoc test. Data in J were analysed using a Kruskal–Wallis test. *P < 0.05; **P < 0.01; ***P < 0.001.